One company is hoping to combine the altered state of the psychedelic experience with the unreal environment of virtual reality (VR) to improve anxiety.
Mydecine Innovations has reported a positive pre-investigational new drug (IND) meeting with America’s Food and Drug Administration (FDA) regarding its psychedelic compound for smoking cessation.
A company is addressing concerns over the medical application of microdosing by developing a molecule that could eliminate the potential risk of heart damage.
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
A new MoU will explore a partnership to utilise MDMA-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD) in Europe.
The world’s first controlled study exploring the use of ketamine-assisted psychotherapy for the treatment of alcohol use disorder (AUD) has shown positive results.
Albert Labs has highlighted that the UK’s new guidance on Real-World data will accelerate access to psychedelic treatments.
A new collaboration is aiming to develop psychedelic medicines to address the unique needs of people living with a variety of mental health conditions.
With the “one-size-fits-all” approach being the norm in the psychiatric industry, HMNC Brain Health is aiming to shake this up through targeted and personalised therapies powered...